Editor’s comment on “CRISPR/Cas9-mediated gene editing in human zygotes using Cas9 protein”

Molecular Genetics and Genomics

Volumn 292, Issue 3, 2017, Pages 535-536

  Hohmann, Stefan ^a  

^a CHALMERS UNIVERSITY OF TECHNOLOGY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

CAS9 PROTEIN; GLUCOSE 6 PHOSPHATE DEHYDROGENASE; PROTEIN; UNCLASSIFIED DRUG; HEMOGLOBIN BETA CHAIN;

CRISPR CAS SYSTEM; DOUBLE STRANDED DNA BREAK; EDITORIAL; EMBRYO; GENE EDITING; HUMAN; NONHUMAN; PRIORITY JOURNAL; WHOLE GENOME SEQUENCING; ZYGOTE; BETA THALASSEMIA; ETHICS; FAVISM; GENE THERAPY; GENETICS; PROCEDURES;

BETA-GLOBINS; BETA-THALASSEMIA; CRISPR-ASSOCIATED PROTEIN 9; CRISPR-CAS SYSTEMS; FAVISM; GENE EDITING; GENETIC THERAPY; GLUCOSEPHOSPHATE DEHYDROGENASE; HUMANS;

EID: 85014118564     PISSN: 16174615     EISSN: 16174623     Source Type: Journal    
DOI: 10.1007/s00438-017-1300-x     Document Type: Editorial

References (4)

1. Callaway E (2016) Second Chinese team reports gene editing in human embryos. Nature. doi:10.1038/nature.2016.19718
2. Kang X et al (2016) Introducing precise genetic modifications into human 3PN embryos by CRISPR/Cas-mediated genome editing. J Assist Reprod Genet 33:581–588. doi:10.1007/s10815-016-0710-8
3. Ledford H (2015) CRISPR, the disruptor. Nature. doi:10.1038/522020a
4. Liang P et al (2015) CRISPR/Cas9-mediated gene editing in human tripronuclear zygotes. Protein Cell 6:363–372. doi:10.1007/s13238-015-0153-5